| Market Cap | 98.26M | P/E | - | EPS this Y | 80.60% | Ern Qtrly Grth | - |
| Income | -12.11M | Forward P/E | -9.98 | EPS next Y | 24.10% | 50D Avg Chg | 18.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | 51.00% |
| Dividend | N/A | Price/Book | 2.16 | EPS next 5Y | - | 52W High Chg | -41.00% |
| Recommedations | 1.00 | Quick Ratio | 29.45 | Shares Outstanding | 9.47M | 52W Low Chg | 108.00% |
| Insider Own | 9.64% | ROA | -30.58% | Shares Float | 5.74M | Beta | 1.54 |
| Inst Own | 23.17% | ROE | -55.76% | Shares Shorted/Prior | 710.90K/545.54K | Price | 10.38 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 778,274 | Target Price | 26.00 |
| Oper. Margin | - | Earnings Date | Jun 8 | Volume | 221,867 | Change | -1.98% |
Hancock Jaffe Laboratories, Inc., a medical device company, develops and sells tissue-based solutions for patients with cardiovascular disease, and peripheral arterial and venous disease in the United States and Europe. It engages in the development and manufacture of bioprosthetic medical devices for cardiovascular diseases, including the VenoValve, a porcine based device to be surgically implanted in the deep venous system of the leg to treat reflux associated with chronic venous insufficiency; and the CoreoGraft, a bovine based off the shelf conduit to be used to revascularize the heart during coronary artery bypass graft surgeries. The company was founded in 1987 and is headquartered in Irvine, California. Hancock Jaffe Laboratories, Inc. is a subsidiary of Leman Cardiovascular SA.